ARQL was down all day, then zoomed up by days end.
I think something is up, but shareholders last to know of course!
Sentiment: Strong Buy
The next for ARQL is ASCO in early June with mCRC Ph2 results. ASCO usually does to not leak info.
But now is the time when ASCO notifies the authors about their abstracts status. ARQL/Qaiichi may leak results.
pharmainvestor or any one ele,can you please tell me where this stock can go with the phase 2 results being good and if it gets fda approved please